Product Data Sheet

LAQ824 (NVP-LAQ824,Dacinostat)

Cat. No.: A4103
CAS No.: 404951-53-7
Formula: C22H25N3O3
M.Wt: 379.46
Synonyms: LAQ-824, NVP-LAQ 824
Target: DNA Damage/DNA Repair
Pathway: HDAC
Storage: Store at -20°C



Solvent & Solubility

In Vitro

insoluble in H2O; insoluble in EtOH; ⩾17.45 mg/mL in DMSO

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	2.6353 mL	13.1766 mL	26.3532 mL
5 mM	0.5271 mL	2.6353 mL	5.2706 mL
10 mM	0.2635 mL	1.3177 mL	2.6353 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	HDAC inhibitor,potent and novel
IC_{50} & Target	32 nM (HDAC)

In Vitro

Cell Viability Assay

Cell Line:	Dexamethasone –sensitive human multiple myeloma (Dex-sensitive MM.1S) cells
Preparation method：	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

	Reacting conditions:	20 nM 24-, 48-, or 72-hour
	Applications:	As an inhibitor of HDAC, LAQ824 induces apoptosis in multiple myeloma cell lines resistant to conventional therapies. In this experiment, Dex or LAQ824 alone produced only 15% and 7% growth inhibition, respectively, but produced 51% inhibition when used in combination.
In Vivo	**Animal experiment**	
	Animal models:	Female BALB/c mice administered 32D.p210 leukemic cells via tail vein injection
	Dosage form:	The mice were given intraperitoneal injection of either 25 mg/kg LAQ824 or D5W vehicle on a daily basis, beginning 3 days after introduction of the leukemic cells.
	Applications:	Treatment of mice with LAQ824 delayed the onset of symptoms of leukemia and lethality as compared to mice treated with the vehicle control. Median survival times were 20 days in the LAQ824-treated mice and 15.5 days in the vehicle control mice.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1. Li N, Yang L, et al. "BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc." Cell Death Dis. 2018 Jul 9;9(7):761.PMID:29988031

See more customer validations on www.apexbt.com.

References

[1] Catley L, Weisberg E, Tai Y T, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 2003, 102(7): 2615-2622.

[2] Weisberg E, Catley L, Kujawa J, et al. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia, 2004, 18(12): 1951-1963.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt

of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com